What is the relative potency ranking of halobetasol propionate, clobetasol propionate, betamethasone dipropionate, and mometasone furoate?

Topical Corticosteroid Potency Ranking

From highest to lowest potency: halobetasol propionate = clobetasol propionate (super-high/Class 1) > betamethasone dipropionate (high-potent/Class 2-3) > mometasone furoate (medium-potency/Class 4-5).

Definitive Potency Classification

Super-High Potency (Class 1)

• Halobetasol propionate 0.05% is classified as a super-high potency corticosteroid 1
• Clobetasol propionate 0.05% is classified as very potent (Class 1) 2
• These two agents demonstrate equivalent clinical efficacy in head-to-head trials, with success rates of 89% vs 93% respectively, showing no statistically significant difference 3
• Both halobetasol and clobetasol are limited to 2 consecutive weeks of use due to significant HPA axis suppression risk 1

High Potency (Class 2-3)

• Betamethasone dipropionate 0.05% is classified as potent (Class 2-3) 2
• Betamethasone dipropionate demonstrates lower potency than both halobetasol and clobetasol in comparative trials, with halobetasol showing 88% success rate versus betamethasone's 78.5% in psoriasis treatment 4
• Clinical studies confirm betamethasone dipropionate and clobetasol propionate have similar efficacy profiles, though clobetasol works slightly faster 5

Medium Potency (Class 4-5)

• Mometasone furoate 0.1% is definitively classified as medium-potency (Class 4-5), not upper-middle potency 6
• The 2021 Joint AAD-NPF Guidelines place mometasone in the middle-potency range based on vasoconstriction activity 6
• Mometasone is grouped with other medium-potency agents such as hydrocortisone valerate 0.2%, fluocinolone acetonide 0.025%, and triamcinolone acetonide 0.1% 6

Clinical Validation of Ranking

Vasoconstrictor Studies

• Direct vasoconstrictor assay data confirm this hierarchy: clobetasol propionate (median blanching 3.00) > betamethasone dipropionate (1.75) = mometasone furoate (2.00) 2
• Novel API potency assessment using Emax modeling ranks inherent potencies as: mometasone furoate > clobetasol propionate, though this contradicts clinical formulation data and should be interpreted cautiously as it measures raw API rather than formulated products 7

Head-to-Head Clinical Trials

• In chronic eczema, clobetasol propionate 0.05% twice daily significantly outperformed mometasone furoate 0.1% once daily, with 88% vs 53% of patients rating treatment as good/excellent 8
• In vulvar lichen sclerosus, clobetasol and mometasone showed similar long-term efficacy (73% vs 81.6% responders), but this reflects maintenance therapy rather than acute potency 9, 10

Clinical Implications

Safety Profile Differences

• Medium-potency steroids like mometasone can be used for longer treatment courses than super-high potency agents due to more favorable adverse-event profiles 6
• Mometasone causes only slight HPA axis suppression with 15g applied twice daily for 7 days to >30% body surface area 11
• Super-high potency agents (halobetasol, clobetasol) require strict 2-week maximum duration and <50g/week dosing limits 1

Formulation Considerations

• The formal potency classification remains constant regardless of vehicle (ointment vs cream), though ointments provide better penetration 6
• Mometasone furoate is FDA-approved as "medium potency" across all formulations 11